Canopy Growth (CGC) EBIT Margin (2019 - 2026)
Canopy Growth (CGC) posted EBIT Margin of 30.87% for Q4 2025, down 21.86% sequentially from 25.33% in Q3 2025, and up 99.0% YoY from 15.51% in Q4 2024.
Canopy Growth (CGC) EBIT Margin (2019 - 2026) Analysis & Trends
Canopy Growth has reported EBIT Margin for 7 years, with the latest figure at 30.87% in Q4 2025.
- Quarterly EBIT Margin rose 99.0% year-over-year to 30.87% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 30.25% (up 4457.0% YoY) and the FY2026 annual result came in at 259.8%, up 67.0% from the prior year.
- EBIT Margin fell to 30.87% in Q4 2025 per CGC's latest filing, from 25.33% in the prior quarter.
- Over five years, EBIT Margin peaked at 134.36% in Q1 2022 and troughed at 1552.6% in Q2 2022.
- A 5-year average of 172.97% and a median of 76.83% in 2023 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2021 and 2022: EBIT Margin jumped 308879 bps in 2021, then plunged 141479 bps in 2022.
- Over 5 years, EBIT Margin stood at 96.73% in 2021, then slumped by 37 bps to 132.81% in 2022, then surged by 42 bps to 76.83% in 2023, then jumped by 59 bps to 31.86% in 2024, then increased by 3 bps to 30.87% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 30.87%, 25.33%, and 31.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | -22.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.03% |
| Dec 31, 2025 | -30.87% |
| Sep 30, 2025 | -25.33% |
| Jun 30, 2025 | -31.36% |
| Dec 31, 2024 | -31.86% |
| Sep 30, 2024 | -72.94% |
| Jun 30, 2024 | -43.96% |
| Mar 31, 2024 | -146.64% |
| Dec 31, 2023 | -76.83% |
| Sep 30, 2023 | -10.07% |
| Jun 30, 2023 | -71.67% |
| Mar 31, 2023 | -468.70% |
| Dec 31, 2022 | -132.81% |
| Sep 30, 2022 | -169.63% |
| Jun 30, 2022 | -1,552.60% |
| Mar 31, 2022 | 134.36% |
| Dec 31, 2021 | -96.73% |
| Sep 30, 2021 | -163.93% |
| Jun 30, 2021 | -137.81% |
| Mar 31, 2021 | -157.10% |